Most people with relapsing or progressive forms of multiple sclerosis (MS) had stable or improved disability scores, along with signs of reduced disease activity, after receiving a single infusion of the experimental CAR T-cell therapy zolacabtagene autoleucel (zola-cel). That’s according to interim results from a Phase 1 clinical trial,…
Discussion
Fewer people with multiple sclerosis (MS) are willing to receive recommended routine vaccines today than before the COVID-19 pandemic, even as neurologists and family doctors talk with them more frequently about immunization, a new study in Germany has found. While vaccination records showed improved coverage for several vaccines, researchers…
Discussion
Most people with progressive forms of multiple sclerosis (MS) had stable or improved disability scores after receiving the experimental CAR T-cell therapy azercabtagene zapreleucel (azer-cel)Â in a small Phase 1 clinical trial. TG Therapeutics, which is developing azer-cel under a licensing agreement with its previous developer, Precision…
Discussion
Early treatment with the experimental oral therapy vidofludimus calcium (IMU-838) may lead to less long-term disability in people with progressive forms of multiple sclerosis (MS), according to new data from the CALLIPER Phase 2 trial and its extension. Immunic, the company developing vidofludimus calcium, presented the findings…
Discussion
Genentech’s experimental oral therapy fenebrutinib may help control the chronic inflammation in the brain associated with disability progression in both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). That’s according to new analyses of data from three ongoing Phase 3 trials, in which…
Get regular updates to your inbox.
